Nearly 1,000 GLP-1 Lawsuits Allege Failure-to-Warn Vision Loss
Mass tort litigation against Novo Nordisk and Eli Lilly is escalating, with nearly 1,000 cases in New Jersey alone alleging the companies failed to warn patients about NAION risk.
Legal entity
Eli Lilly and Company
Company LLYEli Lilly and Company is most often covered alongside GLP-1 Receptor Agonists, which appears in 2 of these 3 stories. They are better corroborated than the beat average, carrying 9.3 original sources each against 3.2 for the same window. The clearest coverage concentration is court-decisions: 2 of 3 stories, with the rest divided among 1 other category.
Last mentioned: Sep 24, 2026
Entity pulse
Recent coverage · Eli Lilly and Company
↑
3 stories
avg impact
0% positive
67% negative
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
What the coverage shows about Eli Lilly and Company
Eli Lilly and Company is most often covered alongside GLP-1 Receptor Agonists, which appears in 2 of these 3 stories. They are better corroborated than the beat average, carrying 9.3 original sources each against 3.2 for the same window. The clearest coverage concentration is court-decisions: 2 of 3 stories, with the rest divided among 1 other category. The 196-day window averages about 0.1 stories each week. At 7, the average consequence score sits above the same-window beat average of 6.2. We currently track 3 Legal stories that mention Eli Lilly and Company, published between March 13, 2026 and September 24, 2026.
- Stories tracked
- 3
- Per week
- 0.1
- Sources per story
- 9.3
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 1630 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Eli Lilly and Company. Shared-story counts are live from our verified record — not editorial picks.
Key Data
Timeline
-
Civil lawsuit against Novo Nordisk reported
The Wall Street Journal reported a civil lawsuit filed against Novo Nordisk by patients who developed NAION after taking Wegovy or Ozempic; similar cases against Eli Lilly are pending.
-
Lawsuit Filed
Novo Nordisk sues Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising and unfair competition under the Lanham Act.
-
Impurity Warning
Lilly issues formal warning after testing reveals impurities in compounded samples.
-
FDA Approves Wegovy 7.2 mg
Novo Nordisk receives U.S. approval for a higher-dose semaglutide injection for obesity, backed by the STEP UP trial showing 19% average weight loss.
-
AAO issues statement on GLP-1s and vision loss
The American Academy of Ophthalmology released a news release urging clinicians and patients to make informed choices about GLP-1 use after studies linked the drugs to vision loss.
-
Compounding Surge
Shortage status triggers Section 503B exemptions, allowing pharmacies to mass-produce compounded versions.
-
Boston medical center issues safety alert
Researchers at a Boston medical facility sent a safety alert flagging a possible connection between GLP-1 medications and NAION.
-
Zepbound Approval
Tirzepatide approved for chronic weight management, exacerbating supply shortages.
-
Mounjaro FDA Approval
FDA approves tirzepatide for type 2 diabetes, leading to immediate high demand.
Stories mentioning Eli Lilly and Company 3
Novo Sues Lilly: Omits Wegovy’s 19% Weight Loss, Seeks Injunction
Novo Nordisk alleges Lanham Act violations; case tests whether outdated comparisons in DTC ads constitute false advertising, with potential precedent for pharma.
Source: rttnews.com · finanznachrichten.de
Lilly Flags Impurities in Compounded GLP-1s, Escalating Regulatory Battle
Eli Lilly has issued a formal warning regarding discovered impurities in compounded versions of its blockbuster weight-loss medication, tirzepatide. This development marks a significant escalation in the ongoing regulatory and legal conflict between pharmaceutical giants and the compounding industry over safety standards and patent enforcement.
Source: kiss1067.iheart.com · power1051.iheart.com
Eli Lilly and Company is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.